Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 228 of 6351
-
Can a Two-Pronged immune attack beat head and neck cancer?
Disease control OngoingThe administration of first-line pembrolizumab monotherapy or combined chemotherapy has been shown to improve survival among patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). However, over 80% of the patients still experience disease progres…
Phase 2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Which steroid best fights ARDS? a Head-to-Head trial aims to find out
Disease control CompletedThe aim of the work is to compare the efficacy of equivalent doses of methylprednisolone, dexamethasone and hydrocortisone in patients with ARDS
Phase 2/3 • Sponsor: Fayoum University • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a robot untangle the nerve pain that Won't quit?
Disease control Recruiting nowThe objective of our study is to evaluate the efficacy of the laparoscopic robot-assited approach after 1 year of follow-up, on pain experience, and anxiety, depression, post-traumatic stress syndrome and quality of life.
Sponsor: UBOSGA • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New combo therapy aims to spare lymph nodes and boost rectal cancer outcomes
Disease control OngoingThis is a randomized, prospective, multicenter, open-label, Phase III clinical trial to evaluate node-sparing modified short-course radiation (Radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes) combined with CAPOX and PD-1 Inhibitor (Tis…
Phase 3 • Sponsor: Sir Run Run Shaw Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Can fewer, stronger radiation doses ease treatment for gynecologic cancers?
Disease control Recruiting nowAfter surgery to remove the main endometrial and/or cervical tumor, most women receive radiation therapy. This study uses hypo-fractionated radiation therapy, which is a type of radiation therapy in which the total prescribed dose of radiation is delivered in fewer but larger dos…
Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New cord blood transplant method aims to beat high-risk blood cancers
Disease control Recruiting nowThis phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic diseases. Giving chemotherapy, such as cyclophosphamide, fludarabine and thiote…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New hope for rare cancers: immunotherapy drug dostarlimab takes on chemo in phase 2 trial
Disease control Recruiting nowThe goal of this open-label randomized, multicenter, comparative phase II trial is to evaluate the efficacy of the immunotherapy, dostarlimab, as first-line treatment for deficient mismatch repair (dMMR)/microsatellite instability (MSI) non-resectable metastatic or locally advanc…
Phase 2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Could a home workout program reshape the gut and tame chemo toxicity?
Disease control Recruiting nowThis research study is a randomized controlled trial that will observe changes in microbiome activity, changes in chemotherapy toxicity, and any changes in treatment outcomes between two groups of participants undergoing chemotherapy with either early-stage or metastatic colorect…
Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a Three-Drug combo outsmart Hard-to-Treat colorectal cancer?
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of fruquintinib and pirfenidone in combination with anti-PD-1 antibody in patients with standard treatment failure of advanced or metastatic pMMR/MSS colorectal adenocarcinoma.
Phase 2 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New trial aims to find best treatment for older lung cancer patients
Disease control Recruiting nowThis phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system atta…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for chronic hives: barzolvolimab in Late-Stage trial
Disease control OngoingThe purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
Phase 3 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can a new drug calm the storm of bipolar mania?
Disease control CompletedThis is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteri…
Phase 3 • Sponsor: Intra-Cellular Therapies, Inc. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New immune therapy shows promise for Tough-to-Treat lymphoma
Disease control Recruiting nowThe goal of this clinical trial is to learn if a new type of chimeric antigen receptor (CAR) T-cell therapy called atlacabtagene autoleucel is effective and safe for the treatment large B-cell lymphomas (LBCL) that have not responded to or have come back after standard chemothera…
Phase 2 • Sponsor: Malaghan Institute of Medical Research • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a new antibody outsmart Hard-to-Treat blood cancer?
Disease control Recruiting nowThis is a 2-part study consisting of a Part 1, dose escalation and dose-finding component to establish the Maximal Tolerated Dose (MTD), or Recommended Part 2 Dose (RP2D) of LIS1 as a single agent; followed by a Part 2, to investigate anti-tumors efficacy of LIS1 in selected subt…
Phase 1/2 • Sponsor: Xenothera SAS • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
One-Time gene therapy could change gaucher treatment forever
Disease control Recruiting nowGaucher disease (GD) is caused by mutations in the GBA1 gene, which leads to a lack or reduction of GCase activity. The consequences of this deficiency are generally attributed to the accumulation of the GCase substrate, Glucosylceramide (GlcCer), in macrophages in the liver, spl…
Phase 1/2 • Sponsor: Lingyi Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Blocking knee blood vessels may offer new pain relief for severe osteoarthritis
Symptom relief Recruiting nowThe goal of this randomized clinical trial is to evaluate the role of genicular artery embolization (GAE) in treating persistent pain in patients with severe knee osteoarthritis who have failed conservative treatment and may be unable to undergo surgical treatment because of sign…
Sponsor: King Abdullah International Medical Research Center • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC
-
Chilled saline infused directly into brain during stroke treatment may limit damage
Disease control CompletedThis is a multicenter, randomized, controlled, subject- and assessor-blinded clinical trial. The research objective is to evaluate the safety and efficacy of selective intra-arterial cooling infusion combined with endovascular therapy in the treatment of acute anterior circulatio…
Sponsor: Beijing Shijitan Hospital, Capital Medical University • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could a Naltrexone-Bupropion combo curb meth addiction? new trial seeks answers
Disease control OngoingThe primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing methamphetamine (MA) use in individuals with moderate or severe methamphetamine…
Phase 3 • Sponsor: National Institute on Drug Abuse (NIDA) • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New trial aims to boost survival in rare blood disease with stem cell transplant
Disease control Recruiting nowThis phase III trial compares the effect of adding a stem cell transplant with melphalan after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD) versus chemotherapy with Dara-VCD alone for treating patients with newly diagnosed am…
Phase 3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can an antimalarial drug boost immunotherapy against colorectal cancer?
Disease control OngoingThis prospective, single-arm study aims to investigate the efficacy and safety of CapeOX combined with anti-PD1 antibody plus dihydroartemisinin as neoadjuvant or conversion therapy for pMMR/MSS locally advanced and metastatic colorectal cancer
Phase 2 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC